Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Thrombocytosis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Specimen Handling 4Biopsy 4Whole-Body Irradiation 3Mycophenolic Acid 3Cyclosporine 3Cyclophosphamide 3fludarabine phosphate 2decitabine and cedazuridine drug combination 2Sirolimus 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Busulfan 2venetoclax 1tocilizumab 1ruxolitinib 1peginterferon alfa-2b 1iadademstat 1fludarabine 1Tacrolimus 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Idarubicin 1Hyperbaric Oxygenation 1Filgrastim 1Etoposide 1Cytarabine 1Cyclosporins 1Cord Blood Stem Cell Transplantation 1Clofarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × peginterferon alfa-2b × 30 days × Clear all
NCT07468916 2026-05-06

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
35 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Thrombocytosis, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡